Workflow
Delcath(DCTH)
icon
Search documents
Delcath Systems Announces Healthcare Setting Locator for HEPZATO™ KIT (melphalan/Hepatic Delivery System)
Prnewswire· 2024-02-22 22:00
NEW YORK, Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website. Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering treatment with the HEPZATO KIT. Sites included on the Locator are accepting inquiries from ...
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prnewswire· 2024-02-16 22:00
NEW YORK, Feb. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January 2024.   The grant totaled the right to purchase an aggregate of 50,000 shares of the ...
Delcath Systems Receives Permanent J-Code (J9248) for HEPZATO™ (melphalan/Hepatic Delivery System) Effective April 1, 2024
Prnewswire· 2024-01-31 13:00
NEW YORK, Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services ("CMS") has established a permanent and product-specific J-code (J9248) for HEPZATO. The J-code will become effective on April 1, 2024. J-codes are a form of Healthcare Common Procedure Coding System Level II identifiers used by payors to streamline the billin ...
Delcath(DCTH) - 2023 Q3 - Earnings Call Transcript
2023-11-14 03:07
Delcath Systems Inc. (NASDAQ:DCTH) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants David Hoffman - General Counsel, Chief Compliance Officer Gerard Michel - CEO Sandra Pennell - SVP, Finance Kevin Muir - General Manager, U.S. Interventional Oncology Conference Call Participants William Maughan - Canaccord Genuity Scott Henry - ROTH Capital Yale Jen - Laidlaw & Co. Operator Good day, and welcome to the Delcath Systems Reports Third Quarter Fiscal Year 2023 Financial Results ...
Delcath(DCTH) - 2023 Q3 - Quarterly Report
2023-11-12 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 10-Q ______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-16133 DELCATH SYSTEMS, INC. (Exact name of regi ...
Delcath(DCTH) - 2023 Q2 - Quarterly Report
2023-08-08 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _____________________ FORM 10-Q ______________________ x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-16133 DELCATH SYSTEMS, INC. (Exact name of registran ...
Delcath(DCTH) - 2023 Q1 - Quarterly Report
2023-05-21 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-16133 DELCATH SYSTEMS, INC. (Exact name of registrant as specified in its charter) Delaware 06-1245881 (State or other j ...
Delcath(DCTH) - 2023 Q1 - Earnings Call Transcript
2023-05-12 14:13
Delcath Systems Inc. (NASDAQ:DCTH) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Gerard Michel - Chief Executive Officer Anthony Dias - Vice President, Finance Kevin Muir - General Manager, U.S. Interventional Oncology David Hoffman - General Counsel, Chief Compliance Officer Conference Call Participants Yale Jen - Laidlaw & Co. Swayampakula Ramakanth - HC Wainwright Bill Maughan - Canaccord Genuity Operator Good day and welcome to the Delcath Systems Reports First Quarter ...
Delcath(DCTH) - 2022 Q4 - Annual Report
2023-03-26 16:00
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 001-16133 DELCATH SYSTEMS, INC. Delaware 06-1245881 definitions of "large accelerated filer," "accelerated filer", "smaller reportin ...
Delcath(DCTH) - 2022 Q3 - Earnings Call Transcript
2022-11-08 18:33
Start Time: 08:30 January 1, 0000 9:00 AM ET Delcath Systems, Inc. (NASDAQ:DCTH) Q3 2022 Earnings Conference Call November 08, 2022, 08:30 AM ET Company Participants Gerard Michel - CEO Anthony Dias - VP of Finance Johnny John - VP, Clinical Development & Medical Affairs Kevin Muir - VP, Commercial Operations David Hoffman - General Counsel, Corporate Secretary and Chief Compliance Officer Conference Call Participants Sam Eiber - BTIG Scott Henry - ROTH Capital Yale Jen - Laidlaw & Company Bill Maughan - Ca ...